Carmofur (HCFU)
Mifurol · Antimetabolite (oral 5-FU prodrug)
Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.
Antimetabolite (oral 5-FU prodrug)
Furtulon · 5dFUR
Antimetabolite (oral 5-FU prodrug) · approved 1987 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Oral 5-FU prodrug (5'-deoxy-5-fluorouridine) with a measurable renal clearance component; kidney risk is conservative and class-level.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
No drug-specific nephrotoxicity incidence is established. Renal risk is inferred at the fluoropyrimidine-class level (rare TMA/HUS); direct doxifluridine renal injury reports are sparse.Source: Gupta et al., Adv Chronic Kidney Dis 2021 (class-level)
Class-level TMA typically after prolonged cumulative exposure.
Distilled from: “Variable; class-level TMA typically after prolonged cumulative exposure.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Thrombotic Microangiopathy strikes: Glomerulus, Vasculature / Endothelium.
Thrombotic Microangiopathy
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
5'-Deoxy-5-fluorouridine is a prodrug converted to 5-fluorouracil, predominantly by pyrimidine nucleoside phosphorylase (thymidine phosphorylase), which is often elevated in tumor tissue. The liberated 5-FU is metabolized to FdUMP and FUTP, inhibiting thymidylate synthase and disrupting RNA/DNA synthesis.
Class-level context for the major non-renal toxicities of the Antimetabolite (oral 5-FU prodrug) class.
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Hematologic
Cytopenias, thrombosis, TMA
Pulmonary
Pneumonitis, ILD, effusions, hypertension
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 225 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
15 of 225 reports
Reported with hospitalization
19 of 225 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 16 of the 225 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. Showing the top 10 of 11 classified systems; 1 lower-ranked system is not drawn. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Doxifluridine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Mifurol · Antimetabolite (oral 5-FU prodrug)
Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.
UFT · Antimetabolite (oral 5-FU prodrug)
Oral tegafur+uracil; rare fluoropyrimidine-class TMA/HUS (often with mitomycin C), otherwise kidney-sparing.
Rasonque · RAS(ON) multi-selective inhibitor
2026 first RAS(ON) inhibitor (mutant + wild-type RAS) for pretreated metastatic pancreatic cancer; creatinine rose in 24% vs 9% on chemotherapy beside 67% diarrhea, and the label names one renal-limited TMA.
Jakafi · JAK1/2 inhibitor
Tumor lysis in myelofibrosis; renally adjusted.
Dacogen · Hypomethylating agent
Tumor lysis in MDS/AML.
Xeloda · Pyrimidine analog (oral 5-FU)
Diarrhea-driven prerenal AKI; dose-adjust for CrCl.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.